---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-237056"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:47:40.786454+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Magenta Q2 loss narrows to $16.9M, cash $207.8M; FDA clinical hold on MGTA-117

## Summary
- Net loss $16.9M in Q2 2021 vs $19.1M in Q2 2020; cash $207.8M sufficient into Q3 2023.
- MGTA-117 IND clinical hold: FDA requires additional bioassay to inform dose escalation; toxicology/manufacturing not at issue.
- Enrollment complete for Phase 2 MGTA-145 + plerixafor in multiple myeloma; final data expected Q4 2021.
- Plans to initiate Phase 2 MGTA-145 trial in sickle cell disease in Q4 2021 with bluebird bio.
- Director Mike Bonney resigned Aug 3; no disagreement; board reduced to 9; Alison Lawton named Chair.

## SEC filing metadata
- accession: 0001193125-21-237056
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312521237056/0001193125-21-237056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312521237056/d206907d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-237056
- JSON: https://secwatch.observer/filing/0001193125-21-237056.json
- Plain text: https://secwatch.observer/filing/0001193125-21-237056.txt

## Key facts
- Executive change
  Michael W. Bonney resigned as Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: resigned
  - Role: Director
  source text: On August 3, 2021, Michael W. Bonney notified the Company of his intent to resign from the Company’s Board of Directors (the “Board”) and its committees effective August 3, 2021, to focus on his newly expanded role as Executive Chair of Alnylam Pharmaceuticals, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312521237056/0001193125-21-237056-index.htm
- Executive change
  Alison F. Lawton was appointed as Chair of the Board at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Chair of the Board
  source text: Alison F. Lawton, currently a member of the Board, was appointed Chair of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312521237056/0001193125-21-237056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.